MEN1 and acute myeloid leukemia: Complementary cell killing activity and more profound epigenetic regulation may be obtained by combined menin and DOT1L inhibition and synergy of these molecules has been observed in preclinical models of both KMT2A-r and NPM1c AML (Dafflon et al., 2017; Kühn et al., 2016).